Crucible Therapeutics

The company was founded by a trio of distinguished academics from the University of Sheffield's Department of Neuroscience: Professor Dame Pamela Shaw, Professor Guillaume Hautbergue, and Professor Mimoun Azzouz. Their collective research, supported by organizations like the Motor Neurone Disease Association and LifeArc, identified that a protein called SRSF1 is a critical factor in the neurotoxicity observed in ALS and FTD. This scientific discovery forms the core of Crucible's therapeutic strategy. Professor Hautbergue, who serves as the Chief Scientific Officer, dedicated over 15 years to studying this therapeutic target before co-founding the company to translate the discovery into a clinical application.

Crucible Therapeutics is developing RNA-based gene therapies designed to target the root causes of these diseases. The company's proprietary approach aims to disrupt the production of toxic proteins that damage neurons by targeting rogue RNA molecules. Specifically, their technology focuses on depleting the SRSF1 protein, which in turn reduces the expression of harmful dipeptide repeat proteins (DPRs), a mechanism implicated in the majority of ALS cases and the most common genetic form of FTD. This method is intended to halt disease progression and potentially allow for the recovery of cognitive function.

The company operates in the biotechnology and drug discovery sectors, functioning as a privately held, venture capital-backed entity. Its business model revolves around advancing its therapeutic candidates through pivotal safety and efficacy studies, with the ultimate goal of initiating human clinical trials. To finance this capital-intensive process, Crucible secured initial seed funding of £5 million in September 2023 from investors Northern Gritstone and Argobio Studio. This was followed by a £2.3 million grant from Innovate UK's Biomedical Catalyst program in June 2025 to scale up manufacturing and advance its lead candidate toward non-clinical safety studies.